PROGNYX

Home/The Watchtower/FDA approves AstraZeneca's Imfinzi plus enfortumab vedoti…

Editorial illustration for the Prognyx briefing on durvalumab (Imfinzi) plus enfortumab vedotin-ejfv, PD-L1 checkpoint inhibitor + Nectin-4 antibody-drug conjugate

Briefing · From the Watchtower

FDA approves AstraZeneca's Imfinzi plus enfortumab vedotin for perioperative MIBC

By · Founder, Prognyx ● Sourced to primary records Oncology
In brief: On 13 November 2026 the FDA approved AstraZeneca's durvalumab (Imfinzi) with enfortumab vedotin-ejfv as neoadjuvant therapy, followed by single-agent durvalumab after radical cystectomy, for adults with muscle-invasive bladder cancer who are ineligible for or refuse cisplatin-based chemotherapy. The clearance rests on VOLGA (NCT04960709), a 695-patient randomized, open-label trial testing the combination against surgery alone and a third investigational arm, with event-free survival by blinded independent review as the primary endpoint.

What the FDA cleared

The FDA approved durvalumab (Imfinzi) with enfortumab vedotin-ejfv as neoadjuvant treatment, then single-agent durvalumab as adjuvant treatment after radical cystectomy, for adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy, on 13 November 2026 [1]. AstraZeneca confirmed the US approval through its newsroom [2]. The clearance sits under BLA 761069, held by AstraZeneca UK [3].

The decision-relevant change is the backbone. The neoadjuvant pairing swaps platinum chemotherapy for an antibody-drug conjugate, enfortumab vedotin, in exactly the patients who cannot receive cisplatin [1]. AstraZeneca's other perioperative bladder program, NIAGARA (NCT03732677), pairs durvalumab with gemcitabine and cisplatin chemotherapy and is active but no longer recruiting [4]. The new regimen gives the franchise a route into the cisplatin-ineligible segment that a platinum backbone cannot serve.

The evidence, and its limits

Approval rests on VOLGA (NCT04960709), a randomized, open-label trial that assigned 695 cystectomy candidates 1:1:1 to neoadjuvant durvalumab plus enfortumab vedotin then adjuvant durvalumab, radical cystectomy alone, or a third investigational combination [1]. The primary endpoint was event-free survival by blinded independent review, with overall survival as an additional outcome measure [1]. Prognyx could not confirm the magnitude of the event-free survival benefit, the overall survival result, or the safety profile from the sources in this dossier.

Who is actually exposed

The shared component is enfortumab vedotin. Summit Therapeutics disclosed HARMONi-GU1, a Phase II/III study of its ivonescimab plus enfortumab vedotin in previously untreated first-line metastatic urothelial carcinoma [6]. That is enfortumab-vedotin-combination competition in urothelial cancer, though in metastatic disease rather than the perioperative setting approved here. The marketed PD-1 and PD-L1 incumbents in urothelial cancer, pembrolizumab (Keytruda) and avelumab (Bavencio), carry metastatic and maintenance indications, not perioperative muscle-invasive disease, so the direct overlap with this approval is narrow [7][8]. Erdafitinib (Balversa) stays biomarker-selected in FGFR3-altered metastatic disease [9].

What to watch, with dates

  • Overall survival from VOLGA: listed as an additional outcome measure and not reported in this dossier [1].
  • The post-approval confirmatory commitment: AstraZeneca's Phase 4 single-arm study in India (NCT07876817) is not yet open [5].
  • Europe: Prognyx could not verify, from a primary EMA or company source, a reported positive CHMP opinion for Merck's pembrolizumab plus enfortumab vedotin in perioperative cisplatin-ineligible MIBC; the one pointer in this dossier is an unresolved news aggregator link.

The now-what

Three moves follow for operators in bladder and urothelial oncology. Teams designing a perioperative MIBC trial now benchmark against a chemo-free immuno-oncology plus ADC comparator in cisplatin-ineligible patients rather than a platinum-only control [1]. Groups holding enfortumab-vedotin-adjacent assets should read the approval as confirmation that the ADC is becoming a combination backbone across sponsors, from AstraZeneca here to Summit Therapeutics in metastatic disease [1][6].

Verdict: a real competitive move in cisplatin-ineligible MIBC, moderate threat to rival perioperative programs, with the window to reposition open now and narrowing as VOLGA overall survival and any EU decisions land.

Questions this briefing answers

Which patients does the new durvalumab plus enfortumab vedotin approval cover?

Adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. They receive neoadjuvant durvalumab plus enfortumab vedotin before radical cystectomy, then single-agent durvalumab afterward [1].

What trial supported the approval?

VOLGA (NCT04960709), a randomized, open-label trial that assigned 695 cystectomy candidates to the durvalumab combination, surgery alone, or a third investigational arm, with event-free survival by blinded independent review as the primary endpoint [1]. The dossier does not carry the effect size or the overall survival result.

Want this on your pipeline?
Get a free sample competitive brief on one of your assets, sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.

Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use.